医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
38期
102-102
,共1页
沈祎%张炜炜%邱君斓%蒋智明
瀋祎%張煒煒%邱君斕%蔣智明
침의%장위위%구군란%장지명
超声造影%肝细胞癌%射频消融%时间强度曲线%血管内皮生长因子
超聲造影%肝細胞癌%射頻消融%時間彊度麯線%血管內皮生長因子
초성조영%간세포암%사빈소융%시간강도곡선%혈관내피생장인자
Hepatocel ular carcinoma%Radiofrequency ablation%Contrast enhanced ultrasonography%Time intensity curve%Vascular endothelial growth factor
目的评估超声造影(CEUS)在肝细胞癌(HCC)行射频消融(RFA)治疗前后的应用价值。方法选取2011年4月~2012年4月于南京市鼓楼医院普外科行RFA治疗HCC患者共24例。术前及术后1个月所有患者常规行CEUS评估,术前计算病灶达峰时间(TTP)与峰值强度(PI),术后判断消融毁损程度。结果肿瘤病灶TTP与血清血管内皮生长因子(VEGF)呈负相关,与肿瘤组织分化程度负相关。 PI与肿瘤相关指标间无明显相关。术后6例患者行CEUS评估示病灶消融不全,与CT/MRI表现及治疗前后肿瘤指标改变相符。结论 CEUS是RFA治疗前后重要的影像评估手段。
目的評估超聲造影(CEUS)在肝細胞癌(HCC)行射頻消融(RFA)治療前後的應用價值。方法選取2011年4月~2012年4月于南京市鼓樓醫院普外科行RFA治療HCC患者共24例。術前及術後1箇月所有患者常規行CEUS評估,術前計算病竈達峰時間(TTP)與峰值彊度(PI),術後判斷消融燬損程度。結果腫瘤病竈TTP與血清血管內皮生長因子(VEGF)呈負相關,與腫瘤組織分化程度負相關。 PI與腫瘤相關指標間無明顯相關。術後6例患者行CEUS評估示病竈消融不全,與CT/MRI錶現及治療前後腫瘤指標改變相符。結論 CEUS是RFA治療前後重要的影像評估手段。
목적평고초성조영(CEUS)재간세포암(HCC)행사빈소융(RFA)치료전후적응용개치。방법선취2011년4월~2012년4월우남경시고루의원보외과행RFA치료HCC환자공24례。술전급술후1개월소유환자상규행CEUS평고,술전계산병조체봉시간(TTP)여봉치강도(PI),술후판단소융훼손정도。결과종류병조TTP여혈청혈관내피생장인자(VEGF)정부상관,여종류조직분화정도부상관。 PI여종류상관지표간무명현상관。술후6례환자행CEUS평고시병조소융불전,여CT/MRI표현급치료전후종류지표개변상부。결론 CEUS시RFA치료전후중요적영상평고수단。
Objective To evaluate the application of contrast-enhanced ultrasonography (CEUS)in Hepatocel ular Carcinoma Undergoing Radiofrequency Ablation.Methods Twenty-four patients with hepatocel ular carcinoma (HCC)undergoing radiofrequency ablation (RFA)in Nanjing Drum Tower Hospital during April 2011 and April 2012 were included in our study.Al patients were routinely examined with CEUS before and 1 month after RFA.Time to peak (TTP)and peak intensity (PI)were calculated during the pre-RFA evaluation and CEUS was used to assess the completeness of RFA 1 month after.Results TTP,instead of PI,was negatively cor elated with serum vascular endothelial growth factor(VEGF)and tumor dif erention degree in HCC patients.1 month after RFA,6 patients showed sign of incomplete ablation on CEUS which was in consistency with CT or MRI findings.Conclusion CEUS is an ef ective method to assess the biological behavior of HCC before RFA and the completeness of ablation after RFA.